RT Journal Article
T1 Fasting Glucose for the Diagnosis of Gestational Diabetes Mellitus (GDM) during the COVID-19 Pandemic
A1 González González, Nieves Luisa
A1 González Dávila, Enrique
A1 Bugatto, Fernando
A1 Vega Guedes, Begoña
A1 Pintado Recarte, María Del Pilar
A1 Tascón, L.
A1 Villalba Martin, Nazaret
A1 Plasencia, Walter
A1 Megía, Ana
AB Background: During the COVID-19 pandemic, different non-validated tests were proposed to simplify the diagnosis of gestational diabetes (GDM). Aim: To analyse the effects of replacing the two-step approach for Early-GDM and GDM diagnosis, with a fasting plasma glucose test. Material and Methods: This is a cohort study consisting of 3200 pregnant women: 400 with Early-GDM, 800 with GDM and 2000 with Non-GDM diagnosed using the two-step approach. Using fasting plasma glucose for Early-GDM and GDM diagnosis, according to the recommendations of Spain, Australia, Italy and the UK during the pandemic, the rates of missed and new Early-GDM and GDM were calculated and perinatal outcomes were analysed. Results: Using fasting plasma glucose in the first trimester >100 mg/dL for Early-GDM diagnosis, the rates of post-COVID missed and new Early-GDM were 79.5% and 3.2%, respectively. Using fasting plasma glucose at 24–28 weeks <84 or >92, 95 or 100 mg/dL for GDM diagnosis, the rates of missed GDM were 50.4%, 78%, 82.6% and 92.4%, respectively, and 8.6%, 5.6% and 2.3% women with Non-GDM were diagnosed with new GDM. Conclusion: Fasting plasma glucose is not a good test for the diagnosis of GDM either in the first trimester or at 24–28 weeks.
PB MDPI
SN 2072-6643
YR 2022
FD 2022-08-20
LK https://hdl.handle.net/20.500.14352/72238
UL https://hdl.handle.net/20.500.14352/72238
LA eng
DS Docta Complutense
RD 19 abr 2025